CA3234818A1 - R-ketamine salts and methods of use thereof - Google Patents
R-ketamine salts and methods of use thereof Download PDFInfo
- Publication number
- CA3234818A1 CA3234818A1 CA3234818A CA3234818A CA3234818A1 CA 3234818 A1 CA3234818 A1 CA 3234818A1 CA 3234818 A CA3234818 A CA 3234818A CA 3234818 A CA3234818 A CA 3234818A CA 3234818 A1 CA3234818 A1 CA 3234818A1
- Authority
- CA
- Canada
- Prior art keywords
- ketamine
- salt
- pxrd
- peaks
- crystalline polymorphic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/06—Oxalic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163254878P | 2021-10-12 | 2021-10-12 | |
| US63/254,878 | 2021-10-12 | ||
| PCT/US2022/046412 WO2023064363A1 (en) | 2021-10-12 | 2022-10-12 | R-ketamine salts and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3234818A1 true CA3234818A1 (en) | 2023-04-20 |
Family
ID=84331621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3234818A Pending CA3234818A1 (en) | 2021-10-12 | 2022-10-12 | R-ketamine salts and methods of use thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240336556A1 (https=) |
| EP (1) | EP4416126A1 (https=) |
| JP (1) | JP2024539623A (https=) |
| CN (1) | CN118647595A (https=) |
| CA (1) | CA3234818A1 (https=) |
| IL (1) | IL312041A (https=) |
| MX (1) | MX2024004478A (https=) |
| WO (1) | WO2023064363A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE056378T2 (hu) | 2013-09-13 | 2022-02-28 | Univ Chiba Nat Univ Corp | R-Ketamin és sójának alkalmazása gyógyszerekként |
| CN119613277A (zh) * | 2023-09-14 | 2025-03-14 | 江苏恩华药业股份有限公司 | 一种(r)-氯胺酮d-酒石酸盐e晶型及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002338680A1 (en) | 2001-09-21 | 2003-04-07 | Solvias Ag | Sealing system with flow channels |
| HUE056378T2 (hu) | 2013-09-13 | 2022-02-28 | Univ Chiba Nat Univ Corp | R-Ketamin és sójának alkalmazása gyógyszerekként |
| US20200405663A1 (en) | 2017-09-27 | 2020-12-31 | National University Corporation Chiba University | R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition functional disorder |
| US11980595B2 (en) | 2018-02-15 | 2024-05-14 | National University Corporation Chiba University | Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases |
| WO2019213551A1 (en) | 2018-05-04 | 2019-11-07 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| WO2020138491A1 (ja) | 2018-12-27 | 2020-07-02 | 国立大学法人千葉大学 | 神経発達障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体 |
-
2022
- 2022-10-12 IL IL312041A patent/IL312041A/en unknown
- 2022-10-12 EP EP22802347.9A patent/EP4416126A1/en active Pending
- 2022-10-12 JP JP2024522124A patent/JP2024539623A/ja active Pending
- 2022-10-12 MX MX2024004478A patent/MX2024004478A/es unknown
- 2022-10-12 US US18/700,013 patent/US20240336556A1/en active Pending
- 2022-10-12 WO PCT/US2022/046412 patent/WO2023064363A1/en not_active Ceased
- 2022-10-12 CN CN202280081833.8A patent/CN118647595A/zh active Pending
- 2022-10-12 CA CA3234818A patent/CA3234818A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024004478A (es) | 2024-07-01 |
| IL312041A (en) | 2024-06-01 |
| EP4416126A1 (en) | 2024-08-21 |
| US20240336556A1 (en) | 2024-10-10 |
| WO2023064363A9 (en) | 2024-02-15 |
| JP2024539623A (ja) | 2024-10-29 |
| WO2023064363A1 (en) | 2023-04-20 |
| CN118647595A (zh) | 2024-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021113225A (ja) | ２−ヒドロキシ−６−（（２−（１−イソプロピル−１ｈ−ピラゾール−５−イル）ピリジン−３−イル）メトキシ）ベンズアルデヒドの遊離塩基の結晶多形 | |
| JP7199739B2 (ja) | Ｇａｂａａの正のアロステリックモジュレーターの塩及び結晶形態 | |
| ES2429348T3 (es) | Cocristales farmacéuticamente aceptables de N-[2-(7-metoxi-1-naftil)etil]acetamida y procedimientos para su preparación | |
| CN101573350A (zh) | 甲磺酸伊马替尼的多晶型及其制备方法以及无定形和α型的甲磺酸伊马替尼 | |
| JP2010527371A (ja) | Ｎ−（４−フルオロベンジル）−ｎ−（１−メチルピペリジン−４−イル）−ｎ’−（４−（２−メチルプロピルオキシ）フェニルメチル）カルバミドならびにその酒石酸塩および各種の結晶形の合成 | |
| JP2025511847A (ja) | ラニフィブラノールの結晶形態 | |
| JP7842805B2 (ja) | フマギロール誘導体およびその多形体 | |
| US20240336556A1 (en) | R-ketamine salts and methods of use thereof | |
| TW202409008A (zh) | 奧比特拉(obicetrapib)鹽及彼等之製造方法與中間體 | |
| EP3743405B1 (en) | Crystalline siponimod fumaric acid and polymorphs thereof | |
| JP2026048695A (ja) | Ｌｓｄ塩結晶形態 | |
| EA005529B1 (ru) | Цитрат 5,8,14-триазатетрацикло-(10.3.1.0.0)-гексадека-2(11),3,5,7,9-пентаена | |
| AU2011334928A1 (en) | Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size | |
| AU2020277881B2 (en) | Crystalline form of sofpironium bromide and preparation method thereof | |
| TW201718516A (zh) | 組蛋白去乙醯酶抑制劑之晶形 | |
| JP2023116756A (ja) | 置換キノキサリン型架橋ピペリジン化合物の多形形態 | |
| EP3360858A1 (en) | Process for producing an aminopyrrolidine derivative | |
| US11208382B2 (en) | Entinostat-containing compound, crystal form of compound thereof, and preparation method therefor and pharmaceutical composition thereof | |
| JP2025524904A (ja) | ダプロデュスタットおよびその共結晶を調整するための方法 | |
| EP2729460B1 (en) | Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride | |
| CN110582279B (zh) | 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶，其制备方法和药物组合物 | |
| CN115448895B (zh) | 一种沃替西汀前药的晶型、其制备方法和应用 | |
| JP7779846B2 (ja) | （１ｒ，３ｓ）－３－（５－シアノ－４－フェニル－１，３－チアゾール－２－イルカルバモイル）シクロペンタンカルボン酸の共結晶 | |
| WO2025228973A1 (en) | Cocrystals of n-{cis-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide | |
| JP5156381B2 (ja) | Ｎ−メチル−Ｎ−（３−｛３−［２−チエニルカルボニル］−ピラゾール−［１，５−α］−ピリミジン−７−イル｝フェニル）アセトアミドの水和物ならびにそれに関連するプロセスおよび方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250613 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250613 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250925 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250925 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251027 |